Research article · 2013
Conference abstractPublished 19 Oct 2018
How do Janus Kinase (JAK) inhibitors really work
Case Western Reserve University School of Medicine, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The Janus Kinase/Signal Transducers and Activators of Transcription (JAK-STAT) signaling pathway plays a prominent role in several autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus, psoriasis/psoriatic arthritis, and, inflammatory bowel disease. Thus, the continuous activation of JAK-STAT signaling mediated by the substantially elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6), IL-17, IL-12/IL-23 and interferon-γ, to name just a few in these diseases, disrupts many of the downstream cellular events regulated by JAK-STAT signaling. This often results in the aberrant survival of immune cells and accessory cells thus perpetuating chronic inflammation. The extent to which JAK-STAT signaling is involved in these autoimmune diseases led to the pre-clinical development and clinical trials evaluation of JAK small molecule inhibitors (SMIs), now referred to as â??Jakinibs.” These include tofacitinib, ruxolitinib, and baricitinib which were FDA-approved for the medical management of RA, psoriasis and myeloproliferative disease. In a pre-clinical analysis, tofacitinib demonstrated a relative selectivity for JAK1/JAK3 compared to JAK1/JAK2. At the cellular level, ruxolitinib, a JAK1/JAK2- selective SMI was shown to reduce the plasma levels of IL-6 and CD-40 as well as the phosphorylation of STAT3 ex vivo using blood cells from RA patients. Conversely, in cell-free assays, baracitinib is relatively selective for JAK1/JAK2 (IC50=5.9/5.7nM, respectively) compared to JAK3 and Tyk2 and exhibits no inhibitory activity towards either the tyrosine-protein kinase Met or checkpoint kinase-2. Baracitinib was also shown to inhibit IL-6-stimulated or IL-23-stimulated phosphorylation of STAT3 as well as the downstream synthesis of the chemokine, monocyte chemoattractant protein-1. At present, studies are being conducted by our research group to determine the extent to which tofacitinib inhibits matrix metalloproteinase gene expression by cultured human chondrocytes.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 27 Mar 2025
Janus Kinase (JAK) Inhibitors: Targeted Therapy in Autoimmune and Inflammatory Diseases
Mini review · 23 Oct 2023
Potential of Janus Kinase (JAK) Inhibitors for Allergic Conditions Complicating Rheumatoid Arthritis (RA): Suppressing the Multiple Immunopathogenic Pathway
Article · 30 Nov 2024
Efficacy of Janus Kinase Inhibitors in the Treatment of Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis
Research article · 26 Apr 2021
Forced Degradation Studies to Assess the Stability of a Janus Kinase Inhibitor Using RPLC Method
More from this journal
The newest in Journal of Clinical and Cellular Immunology.
Perspective · 10 Sep 2026
Cellular Pathways Involved in Mucosal Immunity and Protection Against Environmental Challenges
Commentary · 22 Jul 2026
From Bench to Bedside: Reframing the CXCL13/CXCR5 Axis as a Non-Redundant Organizer of Protective Pulmonary Immunity in COVID-19
Commentary · 17 Jul 2026
CD5L:p40, a third wheel to IL-12 and IL-23 biology?
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Cellular Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Charles J Malemud”

